Mexonup

Sildenafil, the active ingredient in Mexonup, is a phosphodiesterase type 5 inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of erectile dysfunction and pulmonary arterial hypertension in adult patients, improving blood flow to target tissues. The drug enhances nitric oxide‑mediated vasodilation, resulting in improved erectile response and reduced pulmonary vascular resistance.

GNH USA supplies Mexonup as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Sildenafil is used to manage conditions related to impaired nitric‑oxide signaling and vascular tone. - Erectile dysfunction: improves the ability to achieve and maintain an erection sufficient for sexual activity. - Pulmonary arterial hypertension: lowers pulmonary arterial pressure and enhances exercise capacity. - Exercise tolerance in pulmonary hypertension: increases functional capacity during physical activity.

Sildenafil may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache - Flushing - Dyspepsia - Nasal congestion

Serious or Rare Side Effects: - Priapism (prolonged erection) - Sudden hearing loss - Severe hypotension

Before initiating therapy, consider the following safety measures. - Medical evaluation: assess cardiovascular status and suitability for PDE5 inhibition. - Nitrate use: contraindicated due to risk of profound hypotension. - Retinal disorders: use with caution in patients with inherited retinal disease. - Hepatic impairment: severe liver disease may require dose adjustment. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Sildenafil can interact with several medicines; awareness of interaction severity helps guide safe use.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): risk of severe hypotension. - Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil exposure. - Alpha‑blockers (certain agents): may cause marked blood pressure drops. - Other PDE5 inhibitors: combined use can lead to toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Antihypertensives: potential additive hypotensive effect. - Protease inhibitors (e.g., ritonavir): may elevate plasma levels.